Holen Sie sich die Stockscreener-App
0.2585
2.46%
0.006
Schlusskurs vom Vortag:
$0.2525
Offen:
$0.269
24-Stunden-Volumen:
2.20M
Relative Volume:
2.47
Marktkapitalisierung:
$13.53M
Einnahmen:
$65.27M
Nettoeinkommen (Verlust:
$-19.15M
KGV:
-0.4164
EPS:
-0.6208
Netto-Cashflow:
$-12.43M
1W Leistung:
-8.42%
1M Leistung:
-31.89%
6M Leistung:
-59.16%
1J Leistung:
-42.19%
1-Tages-Spanne:
$0.2518
$0.2937
1-Wochen-Bereich:
$0.2464
$0.2937
52-Wochen-Spanne:
$0.2464
$1.32
Cosmos Health Inc Stock (COSM) Company Profile
Firmenname
Cosmos Health Inc
Sektor
Branche
Telefon
312-536-3102
Adresse
5 AGIOU GEORGIOU, PILEA, THESSALONIKI
Compare COSM vs MCK, COR, CAH, HSIC, AHG
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COSM
Cosmos Health Inc
|
0.2585 | 13.21M | 65.27M | -19.15M | -12.43M | -0.6208 |
MCK
Mckesson Corp
|
753.95 | 92.09B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
271.98 | 53.49B | 328.68B | 2.55B | 1.56B | 13.03 |
CAH
Cardinal Health Inc
|
201.02 | 47.00B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
73.94 | 8.45B | 13.18B | 419.00M | 521.00M | 3.2704 |
AHG
Akso Health Group Adr
|
1.615 | 1.31B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cosmos Health Inc Aktie (COSM) Neueste Nachrichten
COSM: Cosmos Health Projects Strong Revenue Growth through 2029 - GuruFocus
Cosmos Health (COSM) Forecasts FY26 Revenue Exceeding $90 Millio - GuruFocus
Cosmos Health projects revenue to reach $200.6M by 2029 - Investing.com Canada
Cosmos Health targets $200 mln revenue, $44 mln adjusted EBITDA by 2029 - marketscreener.com
Cosmos Health Targets $200 Mln Revenue, $44 Mln Adjusted EBITDA By 2029 - TradingView
From $19M loss to $31M profit: Cosmos Health maps 2029 turnaround - Stock Titan
Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash G - StreetInsider
Cosmos Health Releases 2026–2029 Guidance: Targeting $200M - GlobeNewswire
Cosmos Health (COSM) Q1 2026: Revenue $17.93M Misses $21.67M Est - GuruFocus
Cosmos Health (NASDAQ: COSM) seeks shareholder votes on equity plan, Series B preferred - Stock Titan
Cosmos Health Q1 2026 Results: Record $17.9M Revenue, Liabilities Down, U.S. Expansion Underway - Minichart
Cosmos Health reports Q1 revenue up 31% to $17.9M; liabilities down $4.5M - TradingView
Cosmos Health (COSM) Q1 revenue up 31% as net loss widens - Stock Titan
Cosmos Health Reports Strong Q1 Results with Record Revenue - GuruFocus
Cosmos Health (COSM) Reports Strong Q1 2026 Revenue Growth - GuruFocus
Cosmos Health’s Series B warrants expire unexercised By Investing.com - Investing.com Nigeria
Cosmos Health’s Series B warrants expire unexercised - Investing.com
Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants - ACCESS Newswire
4.87M Cosmos Health warrants expire with no new shares issued - Stock Titan
Cosmos Health reports Q1 revenue of $17.9M, up 31% year-over-year By Investing.com - Investing.com South Africa
Cosmos Health reports Q1 revenue of $17.9M, up 31% year-over-year - Investing.com Australia
Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway - ACCESS Newswire
BRIEF-Cosmos Health Q1 Revenue USD 17.9 Million - TradingView
Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues Into Q2 With U.S. Expansion Underway - 富途牛牛
COSM Shows Rapid Revenue Rise - Yahoo Finance
Cosmos Health Inc. 1Q 2026: Revenue $17.93M, EPS ($0.06) — 10-Q Summary - TradingView
Cosmos Health (NASDAQ: COSM) posts Q1 loss and issues going‑concern warning - Stock Titan
Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB's Venture Debt P - ACCESS Newswire
Cosmos Health Company Profile & Introduction - Moomoo
COSM Q1'26 Earnings: EPS estimate is (0.01) USD - TradingView
Cosmos Health Inc stock (US22143K1016): volatility after reverse split and uplisting plans draw inve - AD HOC NEWS
Cosmos Health Inc.Common Stock (NQ: COSM - FinancialContent
[NT 10-Q] Cosmos Health Inc. SEC Filing - Stock Titan
Cosmos Health (COSM) Engages European Investment Bank for R&D Fi - GuruFocus
Cosmos Health stock (US22143K1016): Pursues €25M EIB financing for R&D - AD HOC NEWS
Cosmos Health pursues €25M EIB financing for R&D program By Investing.com - Investing.com South Africa
Cosmos Health pursues €25M EIB financing for R&D program - Investing.com
Cosmos Health regains compliance with Nasdaq’s listing rule - MSN
Cosmos Health (COSM) Withdraws Registration Statement for Public Offering - GuruFocus
TradingKey - TradingKey
Cosmos Health stock (US22143K1016): Fort18 launch targets $3.2M revenue boost - AD HOC NEWS
Cosmos Health withdraws SEC registration statement - Investing.com UK
Cosmos Health withdraws SEC registration statement By Investing.com - Investing.com South Africa
Cosmos Health Announces Withdrawal of Registration Statement on Form S-1 - ACCESS Newswire
Cosmos Health scraps public offering, pulls SEC registration - Stock Titan
Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months - Digital Journal
[RW] Cosmos Health Inc. SEC Filing - Stock Titan
Men's stamina supplement Fort18 targets $3.2M U.S. sales - Stock Titan
Finanzdaten der Cosmos Health Inc-Aktie (COSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cosmos Health Inc-Aktie (COSM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Siokas Grigorios | Chief Executive Officer |
Feb 11 '26 |
Buy |
0.41 |
291,262 |
120,000 |
8,473,382 |
| Siokas Grigorios | Chief Executive Officer |
Jan 23 '26 |
Buy |
0.50 |
90,325 |
45,000 |
8,182,120 |
| Siokas Grigorios | Chief Executive Officer |
Jan 20 '26 |
Buy |
0.50 |
353,321 |
175,000 |
8,091,795 |
| Siokas Grigorios | Chief Executive Officer |
Jan 14 '26 |
Buy |
0.45 |
493,495 |
220,000 |
7,738,474 |
| Siokas Grigorios | Chief Executive Officer |
Jan 12 '26 |
Buy |
0.50 |
113,185 |
57,000 |
7,244,979 |
| Siokas Grigorios | Chief Executive Officer |
Jan 08 '26 |
Buy |
0.52 |
156,190 |
81,000 |
7,131,794 |
| Siokas Grigorios | Chief Executive Officer |
Jan 07 '26 |
Buy |
0.52 |
124,880 |
65,000 |
6,975,604 |
| Siokas Grigorios | Chief Executive Officer |
Jan 06 '26 |
Buy |
0.54 |
133,953 |
72,000 |
6,850,724 |
| Siokas Grigorios | Chief Executive Officer |
Dec 19 '25 |
Buy |
0.49 |
88,314 |
43,000 |
6,716,771 |
| Siokas Grigorios | Chief Executive Officer |
Dec 15 '25 |
Buy |
0.42 |
168,472 |
70,000 |
6,628,457 |
2.29%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):